Ionis Pharmaceuticals (FRA:ISI) NonCurrent Deferred Liabilities: €54.7 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ISI Ionis Pharmaceuticals Inc FRA:ISI
71 GF Score
Price €46.56
GF Value €41.63
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals NonCurrent Deferred Liabilities?

Ionis Pharmaceuticals FRA:ISI -3.14% 71 NonCurrent Deferred Liabilities is €54.7 Mil as of Jun. 2026. GuruFocus rates FRA:ISI with a GF Score™ of 71/100 and a GF Value™ of €41.63 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Ionis Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Jun. 2026 was €54.7 Mil.

Ionis Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Ionis Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals NonCurrent Deferred Liabilities Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 311.41 271.65 221.17 149.46 78.57

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.46 91.94 78.57 65.52 54.71
FRA:ISI
71GF Score
Ionis Pharmaceuticals Inc FRA:ISI
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €54.7 Mil mean?
Ionis Pharmaceuticals (FRA:ISI) has a NonCurrent Deferred Liabilities of €54.7 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' NonCurrent Deferred Liabilities too high?
Ionis Pharmaceuticals' current NonCurrent Deferred Liabilities is €54.7 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' NonCurrent Deferred Liabilities compare to KYMR and PRAX?
Ionis Pharmaceuticals' NonCurrent Deferred Liabilities of €54.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current NonCurrent Deferred Liabilities is €54.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Modestly Overvalued. The stock's GF Value™ is €41.63, compared to a current price of €46.56 — trading 11.8% above its estimated fair value. The current NonCurrent Deferred Liabilities is €54.7 Mil. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current NonCurrent Deferred Liabilities is €54.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €46.56 is trading 11.8% above its estimated GF Value™ of €41.63. GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FRA:ISI:

  • NonCurrent Deferred Liabilities: €54.7 Mil
  • GF Value™: €41.63 vs. price of €46.56 (11.8% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA1IONS:Italy0JDI:UK
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score

Get the complete analysis for FRA:ISI

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.56
Price
€41.63
GF Value